<DOC>
	<DOCNO>NCT00015925</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I trial study effectiveness MS-275 treating patient hematologic cancer .</brief_summary>
	<brief_title>MS-275 Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxic effect pharmacokinetics MS-275 patient poor-risk hematologic malignancy . - Determine whether drug induces change hematologic differentiation , term change morphology , cell surface marker expression , acetylation status , patient . - Determine whether drug induces clinical response patient . OUTLINE : This dose-escalation study . Patients receive oral MS-275 day 1 , 8 , 15 , 22 . Courses repeat every 6 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos MS-275 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 25-30 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow histologically confirm diagnosis : Acute myeloid leukemia ( AML ) Newly diagnose de novo AML patient 60 year old follow poorrisk feature : Antecedent hematologic disorder Complex karyotype adverse cytogenetics Stem cell immunophenotype AML arise myelodysplastic syndrome ( MDS ) Secondary AML Relapsed refractory AML , include primary induction failure MDS Poorrisk , define follow : International Performance Score least 1.5 More 10 % marrow blast Cytopenias least 2 lineage Refractory anemia excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia Acute lymphoblastic leukemia ( ALL ) Newly diagnose de novo ALL patient 60 year old follow poorrisk feature : Complex karyotype adverse cytogenetics Mixed lineage immunophenotype Relapsed refractory ALL , include primary induction failure Chronic myelogenous leukemia ( CML ) CML accelerate phase blast crisis Interferonrefractory CML chronic phase Multiple myeloma ( MM ) Relapsed refractory , include prior autologous stem cell transplantation Acute promyelocytic leukemia Prior treatment tretinoin Ineligible arsenic trioxide No evidence active coagulopathy Lowrisk develop clinically significant coagulopathy study Low tumor burden marrow aspiration time relapse No prior coagulationrelated sequela ( deep vein thrombosis , pulmonary embolism , CNS thrombosis bleed ) Failure primary induction therapy relapse complete remission allow patient receive 3 course prior induction/reinduction therapy Not eligible curative stem cell transplantation No hyperleukocytosis least 50,000/mm^3 leukemic blast No active CNS leukemia No plasma cell leukemia No amyloidosis result major organ dysfunction PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics No disseminate intravascular coagulation No hyperviscosity Hepatic : AST/ALT great 2 time normal Alkaline phosphatase great 2 time normal Bilirubin great 1.5 time normal Renal : Creatinine great 1.5 time normal No uncorrected hypercalcemia Cardiovascular : See Disease Characteristics LVEF least 45 % MUGA echocardiogram No intrinsic impaired cardiac function , include follow : Myocardial infarction within past 3 month Prior severe coronary artery disease Cardiomyopathy Congestive heart failure Other : No active uncontrolled infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 1 week since prior growth factor ( epoetin alfa , filgrastim [ GCSF ] , sargramostim [ GMCSF ] , interleukin [ IL ] 3 , IL11 ) At least 4 week since prior autologous stem cell transplantation No prior allogeneic stem cell transplantation No concurrent immunotherapy Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy recover At least 24 hour since prior hydroxyurea mercaptopurine prevention leukostasis No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 2 week since prior emergency radiotherapy large soft tissue lytic bony lesion MM No concurrent radiotherapy Surgery : Not specify Other : At least 24 hour since prior noncytotoxic agent prevention leukostasis No concurrent antitumor therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>